Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,944 result(s) found for: Liver Diseases. Displaying page 75 of 198.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    EudraCT Number: 2019-001478-27 Sponsor Protocol Number: IRFMN-GCC-7813 Start Date*: 2019-09-11
    Sponsor Name:Associazione Chirurghi Ospedalieri Italiani
    Full Title: Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcomes....
    Medical condition: Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007350 Carcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002366-41 Sponsor Protocol Number: AIEOP-ISGOsM+ Start Date*: 2021-09-28
    Sponsor Name:ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma
    Medical condition: Metastatic osteosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031294 Osteosarcoma metastatic PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003008-15 Sponsor Protocol Number: CAPRI2 Start Date*: 2021-05-27
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.
    Medical condition: mCRC patients with RAS/BRAF wild type tumors at start of first line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003227-21 Sponsor Protocol Number: SGC-AX14 Start Date*: 2014-10-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori Milano
    Full Title: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract
    Medical condition: recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10051975 Salivary gland carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000355-37 Sponsor Protocol Number: MEC-2022-0373 Start Date*: 2022-08-29
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
    Medical condition: Operable patients ≥ 18 years of age with locoregionally advanced squamous cell- or adenocarcinoma of the esophagus or esophagogastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003078-10 Sponsor Protocol Number: SPCG 16 Start Date*: 2011-11-02
    Sponsor Name:SPCG
    Full Title: SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer
    Medical condition: Patients diagnosed with metastatic or high risk(PSA>100 or N1) prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001284-27 Sponsor Protocol Number: ENHANCE Start Date*: 2022-09-07
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial
    Medical condition: NSCLC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003203-14 Sponsor Protocol Number: TUXEDO-2 Start Date*: 2023-05-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Medizin I, Onkologie
    Full Title: Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases
    Medical condition: triple negative breast cancer with newly diagnosed or progressing brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003970-41 Sponsor Protocol Number: CRU3 Start Date*: 2017-07-06
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS
    Medical condition: Anaplastic Large Cells Lymphoma (ALCL) ALK+
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000967-25 Sponsor Protocol Number: ThoRaT Start Date*: 2012-08-24
    Sponsor Name:
    Full Title: Concomitant Radiotherapy and Erlotinib in advanced lung cancer ThoRaT-studien Thoracal Radiotherapy and Tarceva® An open randomized multicenter phase II study
    Medical condition: Non-small cell lung cancer, - palliative treatment
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003792-41 Sponsor Protocol Number: DAROTAXEL Start Date*: 2023-05-26
    Sponsor Name:Erasmus MC
    Full Title: A randomized phase II trial of docetaxel or cabazitaxel with or without darolutamide in men with metastatic castration-resistant prostate cancer.
    Medical condition: metastatic castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004850-17 Sponsor Protocol Number: FOLFOXIRI-Toco Start Date*: 2016-02-19
    Sponsor Name:Vejle Hospital
    Full Title: A randomized investigation of side effects to FOLFOXIRI in combination with tocotrienol or placebo as first line treatment of metastatic colorectal cancer.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001237-41 Sponsor Protocol Number: NLCG-2013.1 Start Date*: 2013-06-05
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: A Randomized Phase III Study Comparing Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer
    Medical condition: Advanced non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005268-71 Sponsor Protocol Number: ML42600 Start Date*: 2021-03-04
    Sponsor Name:Roche Farma S.A.
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN SPANISH PATIENTS WITH UNRESECTABLE OR UNSUITABLE FOR LOCOREGIONAL ...
    Medical condition: Treatment for patients with unresectable HCC who have received no prior systemic treatment and are considered unsuitable for locoregional therapy.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004113-13 Sponsor Protocol Number: CLDE225XBE01T Start Date*: 2012-11-05
    Sponsor Name:GZA vzw, GZA Ziekenhuizen, Sint-Augustinus
    Full Title: A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors
    Medical condition: Basal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002756-21 Sponsor Protocol Number: 1663/2020 Start Date*: 2021-02-23
    Sponsor Name:Department of Cardiothoracic Anesthesia and Intensive Care Medicine, Medical University of Vienna
    Full Title: Plasma Pharmacokinetics of Prophylactic Cefazolin Administered for Cardiac Surgery: Comparison of Cardiopulmonary Bypass Priming with Additive Human Albumin 20% vs.Pure Crystalloid Priming: A singl...
    Medical condition: This is a pharmacokinetic trial for patients undergoing cardiac surgery. It will be investigated whether cardiopulmonary bypass priming substituted with human albumin 20% has an effect on the pharm...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2025-000263-36 Sponsor Protocol Number: JZP458-201 Start Date*: 2025-10-05
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases
    Medical condition: Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-003684-35 Sponsor Protocol Number: R2810-ONC-1763 Start Date*: 2018-07-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients wit...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-000515-41 Sponsor Protocol Number: A5481044 Start Date*: 2015-11-09
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/META...
    Medical condition: RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PL (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 21:51:51 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA